Is Edesa Biotech Stock a Good Investment?
Edesa Biotech Investment Advice | EDSA |
- Examine Edesa Biotech's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Edesa Biotech's leadership team and their track record. Good management can help Edesa Biotech navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Edesa Biotech's business and its evolving consumer preferences.
- Compare Edesa Biotech's performance and market position to its competitors. Analyze how Edesa Biotech is positioned in terms of product offerings, innovation, and market share.
- Check if Edesa Biotech pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Edesa Biotech's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Edesa Biotech stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Edesa Biotech is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Edesa Biotech Stock
Researching Edesa Biotech's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 29.0% of the company shares are held by company insiders. The book value of Edesa Biotech was currently reported as 0.91. The company recorded a loss per share of 1.55. Edesa Biotech last dividend was issued on the 10th of June 2019. The entity had 1:7 split on the 11th of October 2023.
To determine if Edesa Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Edesa Biotech's research are outlined below:
| Edesa Biotech generated a negative expected return over the last 90 days | |
| Net Loss for the year was (6.17 M) with profit before overhead, payroll, taxes, and interest of 311.2 K. | |
| Edesa Biotech currently holds about 12.81 M in cash with (4.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83. | |
| Edesa Biotech has a frail financial position based on the latest SEC disclosures | |
| Roughly 29.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 132845 shares by Van Der Velden Peter of Edesa Biotech at 2.6621 subject to Rule 16b-3 |
Edesa Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Edesa Biotech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Edesa Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 9th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of December 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Edesa Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Edesa Biotech's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-12-07 | 2020-09-30 | -0.2 | -0.22 | -0.02 | 10 | ||
2020-05-15 | 2020-03-31 | -0.19 | -0.17 | 0.02 | 10 | ||
2022-05-13 | 2022-03-31 | -0.37 | -0.33 | 0.04 | 10 | ||
2021-08-13 | 2021-06-30 | -0.32 | -0.36 | -0.04 | 12 | ||
2023-05-11 | 2023-03-31 | -0.17 | -0.12 | 0.05 | 29 | ||
2024-08-09 | 2024-06-30 | -0.58 | -0.52 | 0.06 | 10 | ||
2023-02-10 | 2022-12-31 | -0.19 | -0.13 | 0.06 | 31 | ||
2022-08-12 | 2022-06-30 | -0.43 | -0.37 | 0.06 | 13 |
Edesa Biotech Target Price Consensus
Edesa target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Edesa Biotech's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Strong Buy |
Most Edesa analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Edesa stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Edesa Biotech, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationEdesa Biotech Target Price Projection
Edesa Biotech's current and average target prices are 2.14 and 13.00, respectively. The current price of Edesa Biotech is the price at which Edesa Biotech is currently trading. On the other hand, Edesa Biotech's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Edesa Biotech Market Quote on 3rd of August 2025
Target Price
Analyst Consensus On Edesa Biotech Target Price
Edesa Biotech Analyst Ratings
Edesa Biotech's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Edesa Biotech stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Edesa Biotech's financials, market performance, and future outlook by experienced professionals. Edesa Biotech's historical ratings below, therefore, can serve as a valuable tool for investors.Know Edesa Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Edesa Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Edesa Biotech backward and forwards among themselves. Edesa Biotech's institutional investor refers to the entity that pools money to purchase Edesa Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Efficient Wealth Management Llc | 2025-03-31 | 242 | Td Waterhouse Canada Inc | 2025-03-31 | 142 | Fifth Third Bancorp | 2025-06-30 | 100.0 | Bank Of America Corp | 2025-03-31 | 22.0 | Ubs Group Ag | 2025-03-31 | 4.0 | Crédit Agricole S.a. | 2025-03-31 | 1.0 | Allsquare Wealth Management Llc | 2025-03-31 | 1.0 | Dogwood Wealth Management Llc | 2025-03-31 | 1.0 | Cm Management, Llc | 2025-03-31 | 0.0 | Velan Capital Investment Management Lp | 2025-03-31 | 687.5 K | Stonepine Capital Management Llc | 2025-03-31 | 687.5 K |
Edesa Biotech's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.04 M.Market Cap |
|
Edesa Biotech's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.44) | (0.46) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (1.10) | (1.15) |
Determining Edesa Biotech's profitability involves analyzing its financial statements and using various financial metrics to determine if Edesa Biotech is a good buy. For example, gross profit margin measures Edesa Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Edesa Biotech's profitability and make more informed investment decisions.
Please note, the presentation of Edesa Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Edesa Biotech's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Edesa Biotech's management manipulating its earnings.
Evaluate Edesa Biotech's management efficiency
Edesa Biotech has return on total asset (ROA) of (0.3529) % which means that it has lost $0.3529 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5878) %, meaning that it created substantial loss on money invested by shareholders. Edesa Biotech's management efficiency ratios could be used to measure how well Edesa Biotech manages its routine affairs as well as how well it operates its assets and liabilities. As of August 3, 2025, Return On Tangible Assets is expected to decline to -0.61. In addition to that, Return On Capital Employed is expected to decline to -0.46. At present, Edesa Biotech's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 2.6 M, whereas Non Currrent Assets Other are forecasted to decline to about 46.3 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 42.65 | 42.08 | |
| Tangible Book Value Per Share | 42.65 | 41.06 | |
| Enterprise Value Over EBITDA | (100.62) | (95.59) | |
| Price Book Value Ratio | 109.59 | 115.07 | |
| Enterprise Value Multiple | (100.62) | (95.59) | |
| Price Fair Value | 109.59 | 115.07 | |
| Enterprise Value | 830.5 M | 872 M |
Leadership at Edesa Biotech emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 0.395 |
Basic technical analysis of Edesa Stock
As of the 3rd of August, Edesa Biotech shows the Mean Deviation of 2.11, standard deviation of 2.79, and Variance of 7.77. Edesa Biotech technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Edesa Biotech's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Edesa Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Edesa Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Edesa Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Edesa Biotech's Outstanding Corporate Bonds
Edesa Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Edesa Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Edesa bonds can be classified according to their maturity, which is the date when Edesa Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Edesa Biotech's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Edesa Biotech's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 2.11 | |||
| Coefficient Of Variation | (2,391) | |||
| Standard Deviation | 2.79 | |||
| Variance | 7.77 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.49) | |||
| Treynor Ratio | (0.25) | |||
| Maximum Drawdown | 11.21 | |||
| Value At Risk | (4.89) | |||
| Potential Upside | 5.26 | |||
| Skewness | 0.4554 | |||
| Kurtosis | 0.6852 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 2.11 | |||
| Coefficient Of Variation | (2,391) | |||
| Standard Deviation | 2.79 | |||
| Variance | 7.77 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.49) | |||
| Treynor Ratio | (0.25) | |||
| Maximum Drawdown | 11.21 | |||
| Value At Risk | (4.89) | |||
| Potential Upside | 5.26 | |||
| Skewness | 0.4554 | |||
| Kurtosis | 0.6852 |
Consider Edesa Biotech's intraday indicators
Edesa Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Edesa Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Edesa Biotech time-series forecasting models is one of many Edesa Biotech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Edesa Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Edesa Stock media impact
There is far too much social signal, news, headlines, and media speculation about Edesa Biotech that are available to investors today. This information is accessible both publicly - through Edesa Biotech's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Edesa-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Edesa Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Edesa Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Edesa Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Edesa Biotech alpha.
Edesa Biotech Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Edesa Biotech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Edesa Biotech Corporate Management
| CPA CPA | Chief Officer | Profile | |
| BA CPA | Chief Officer | Profile | |
| Dr MBA | President | Profile | |
| MSc MBA | Chief Officer | Profile | |
| Gary Koppenjan | VP Communications | Profile | |
| MD FRCPC | Company CEO | Profile | |
| Rajan Puri | VP Manufacturing | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Edesa Biotech's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.